CClinicalTrials.gg
CompletedNCT03279536TDIUpdated Oct 27, 2020

Lactoferrin Versus Total Dose Infusion (TDI) For Treating Iron Deficiency Anemia in Pregnancy: Role of Nursing

A Phase 1/2 interventional study of Oral lactoferrin and TDI of LMW iron dextran in Iron Deficiency Anemia, sponsored by Woman's Health University Hospital, Egypt. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2020-10-27.

Sponsored by Woman's Health University Hospital, Egypt · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This study consisted of 60 cases. All the cases of pregnant women are 4 months to 8 months of pregnancy. The cases divided into 30 pregnant women's were given iron supplementation without health education and another 30 were given iron supplementation and health education for comparison between them. Comparative between hemoglobin levels before and after medication. Treatment of iron deficiency anemia with iron supplementation received for one month.

Read the detailed description

The investigator will divide the participants into two groups e.g. group (A) and group (B) according to Hemoglobin level and receiving of oral supplementation for IDA accompanied with health education in case of group (A) and without health education in case of group (B). Then the investigator asked patient to sign the document of her investigations result to receive iron supplementation.

  • After that, the investigator observes hemoglobin's Level, when it less than >11g/dl, the patient will be the group (A) who will receive oral iron supplementation and health education.
  • Group (B) who will receive Total Dose Infusion (TDI) without health education.
02

Conditions studied

03

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Pregnant Women aged >18 years
  2. Hemoglobin\<10g/dl
  3. Gestational age between 14-28 weeks
  4. Singleton pregnancy
  5. Willingness to participate and signing the informed consent form

Exclusion criteria

Exclusion Criteria:

  1. Anemia predominantly caused by factors other than IDA (e.g. anemia with untreated B12 or foliate deficiency, hemolytic anemia),
  2. Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and haemosidrosis).
  3. Decompensated liver cirrhosis and active hepatitis (ALAT>3 times upper limit of normal).
  4. Active acute or chronic infections (assessed by clinical judgment supplied with white Blood Cells (WBC) and C - reactive protein (CRP).
  5. Rheumatoid arthritis with symptoms or signs of active inflammation.
  6. Multiple allergies.
  7. Known hypersensitivity to parental iron or any recipients in the investigational drug products.
  8. Erythropoietin treatment within 8 weeks prior to the screening visit.
  9. Other iron treatment within 8 weeks prior to the screening visit.
  10. Planned elective surgery during the study.
  11. Participation in any other clinical within 3 months prior to the screening.
  12. Any other medical condition e.g. malignancy, uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus.
04

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Oral Lactoferrin

    Group A is 120 mg of Oral lactoferrin for 4 weeks Intervention: The participants 66 will receive oral Lactoferrin 120mg for 4 weeks

    Combination Product: Oral lactoferrin

  • Active comparator
    Total dose infusion (TDI) iron dextran

    Group B is a parenteral total dose infusion (TDI) of LMW iron dextran 20mg/kg body weight for 4 weeks Intervention: The participants 33 will receive parental iron 20mg/kg body weight for 4 weeks

    Combination Product: TDI of LMW iron dextran

Interventions

  • Combination productOral lactoferrin

    Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.

    Also known as: Oral Fizzing Lactoferrin

  • Combination productTDI of LMW iron dextran

    Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously

    Also known as: Parental dextran

05

What researchers measure

Primary outcomes

  1. the change in Hb concentration

    measure the change in Hb concentration from baseline to week 4 after oral Lactoferrin treatment and relieve of symptoms of anemia

    Time frame: 4- 8 weeks

Secondary outcomes

  1. measure the change in serum iron, serum ferritin

    measure the change in serum iron, serum ferritin based on comparison between oral lactoferrin with health education \& TDI from hospital routine care.

    Time frame: 4-8 weeks

06

Study locations

1 site
  • Women Health Hospital
    Asyut, 71111, Egypt
07

References and documents

Individual participant data

Plan to share: Yes — Publishing

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03279536
Lead sponsor
Woman's Health University Hospital, Egypt
Responsible party
Howieda Fouly (PhD of Obstetric & Gynecologic Nursing, Woman's Health University Hospital, Egypt) — Principal investigator
First posted
Sep 12, 2017
Start date
Nov 1, 2017
Primary completion
Dec 30, 2018
Completion
Dec 30, 2018
Last update
Oct 27, 2020

Study contacts

Warda Helmy, BSN
principal investigator · WHH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion